While Novo Nordisk currently has a head start, with 55% of drugs still in Phase 1 and competition heating up, the company must navigate challenges to maintain its meteoric growth
In order to address the issue of therapeutic resistance driven by reprogramming of tumor glutamine metabolism, future studies must thoroughly examine the heterogeneity of glutamine dependence in different genetic backgrounds (e.g., KRAS-mutant vs
And individual response varies significantly
For semaglutide users concerned about muscle preservation and joint health during rapid weight loss, glycine offers benefits that pyridoxine does not
The FDA declared in February 2025 that the supply issues for both Ozempic and Wegovy have been resolved, reducing the need for compounded alternatives
Peptide Therapy works by delivering short chains of amino acids that signal your body to heal, burn fat, and build lean musclemaking it a perfect partner for your B12 shot